Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: Results of a randomized, double-blind study

Journal of Pediatric Gastroenterology and Nutrition

Volumn 49, Issue 5, 2009, Pages 571-579

  Quiros, J Antonio ^a   Heyman, Melvin B ^b   Pohl, John F ^c   Attard, Thomas M ^d   Pieniaszek, Henry J ^e   Bortey, Enoch ^f   Walker, Kelli ^f   Forbes, William P ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e HPP Consulting and Services Inc   (United States)

^f Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

5 Aminosalicylates; Inflammatory bowel disease; Pharmacokinetics; Ulcerative colitis.

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; BALSALAZIDE; MESALAZINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CHOLECYSTITIS; CLINICAL TRIAL; COLON BIOPSY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION URGENCY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTRITIS; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEPHROTOXICITY; PANCREATITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; UPPER ABDOMINAL PAIN; URTICARIA; VOMITING;

ADOLESCENT; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS; CHILD; COLITIS, ULCERATIVE; COLON; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MESALAMINE; PHENYLHYDRAZINES;

EID: 70350648757     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31819bcac4     Document Type: Article

References (22)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-1385
2. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007;13:254-261
3. Bousvaros A, Sylvester F, Kugathasan S, et al. Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2006; 12:885-913. (Pubitemid 44352716)
4. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;CD000543.
5. Lim WC, Hanauer SB. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord 2004;4: 104-117
6. BremnerAR, GriffithsDM,BeattieRM.Current therapyof ulcerative colitis in children. Expert Opin Pharmacother 2004;5: 37-53.
7. Ferry GD, Kirschner BS, Grand RJ, et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gastroenterol Nutr 1993;17:32-38
8. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19:179-189
9. Mansfield JC, Giaffer MH, Cann PA, et al. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002;16:69-77.
10. Green JR, Mansfield JC, Gibson JA, et al. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002;16:61-68
11. Product information for Colazal (balsalazide disodium) capsules, Salix Pharmaceuticals Inc.
12. Chan RP, Pope DJ, Gilbert AP, et al. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci 1983;28:609-615
13. Prakash A, Spencer CM. Balsalazide. Drugs 1998;56:83-89
14. Product information for Pentasa (mesalamine) controlled-release capsules 250mg, Shire US Incorporated.
15. Product information for Asacol (mesalamine) delayed-release tablets, Procter & Gamble Pharmaceuticals.
16. Product information for Lialda (mesalamine) delayed-release tablets, Shire US Inc.
17. McIntyre PB, Rodrigues CA, Lennard-Jones JE, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther 1988;2:237-243
18. Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mildto- moderate ulcerative colitis. Am J Gastroenterol 2002;97:1398-1407
19. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-1898 (Pubitemid 17072238)
20. Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 2004;18:509-523
21. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:3078-3086
22. Turner D, Hyams J, Markowitz J, et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis 2009; epub ahead of print, January 22.